Nachrichten zur JOHNSON MATT. LS 1,101698 Aktie

The celebrity doctor’s 2022 financial disclosure for his Senate run details holdings in stocks like UnitedHealth, CVS and Johnson &…

…

…

…

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple…

mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.…

Todays Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and…

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide. It is set…

Fewer contenders means fewer constraints on expanding market share.…

Fewer contenders means fewer constraints on expanding market share.…

Wien (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI),…

Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.…

Starboard Value has amassed a significant stake in Kenvue, which spun out of Johnson & Johnson in mid-2023.…

New York (www.aktiencheck.de) - Rating-Update: Joanne Wuensch, Analystin der Citigroup, bewertet die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046, WKN:…

Kaum ein Unternehmen schüttet so sicher Dividenden aus wie Johnson & Johnson. Und seit 62 Jahren steigen sie kontinuierlich und…

…

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets: Rating und Kursziel RBC Capital Markets hat das Kursziel für Johnson &…

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley: Morgan Stanley erhöht Kursziel auf 175 USD Der Analyst Terence Flynn von…

Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on…

Am US-amerikanischen Aktienmarkt ist der Anteilsschein von Johnson & Johnson aktuell unauffällig. Das Papier kostete zuletzt 164,46 US-Dollar. Kaum auffällig…

St. Louis (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Stifel: Stifel hat das Kursziel für Johnson & Johnson (ISIN: US4781601046, WKN: 853260,…

San Francisco (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Wells Fargo Advisors: Wells Fargo hat das Kursziel für Johnson & Johnson (ISIN:…

JNJ earnings call for the period ending September 30, 2024.…

…

…

Bank of America (BAC), Goldman Sachs (GS), Johnson & Johnson (JNJ) and UnitedHealth (UNH) are the stocks to watch on…

US stock futures (ES=F, NQ=F, YM=F) are flat Tuesday morning coming off the Dow Jones Industrial Average (^DJI) and S&P…

Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per...…

Die Berichtssaison in den USA nimmt peu à peu an Fahrt auf. Traditionell gehört Johnson & Johnson neben den großen…

Johnson & Johnson reports Q3 beat, raises sales guidance…

United Health, Johnson & Johnson lead Tuesdays earnings lineup…

Charles Schwab, Bank of America, Johnson & Johnson, Walgreens, UnitedHealth Group Morgan Stanley, Procter & Gamble and Abbott Laboratories all…

Johnson & Johnson said it will discontinue a mid-stage field study evaluating the efficacy of its experimental pill for the…

Johnson & Johnson discontinues dengue drug study…

Wells Fargo says there is a risk that Johnson & Johnson will guide lower…

Johnson & Johnsons new facility will create 420 jobs in Wilson County.…

Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at…

Der Kurs der dem Anteilsschein von Johnson & Johnson kommt kaum von der Stelle. Der jüngste Kurs betrug 161,13 US-Dollar.…

Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.…

…

This healthcare blue chip is making all the right moves to reward shareholders.…

Thursday, the FDA approved Johnson & Johnson (NYSE:JNJ) Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally…